Symptom management in patients with multiple sclerosis

Multiple sclerosis is a complex disease associated with a wide variety of different symptoms that can affect the ability of multiple sclerosis patients to carry out normal activities of daily living. Although a myriad of symptoms can afflict these patients, the most commonly reported include fatigue, mood disorders, changes in cognitive function or memory, sensory changes (numbness, pain, vibrations), motor changes (loss of balance, poor coordination, muscle weakness or stiffness), vision changes (double vision, blurred vision, loss of vision) and bladder or bowel dysfunction. Treatments are available that can help minimise some of these symptoms and relieve patient distress. After the diagnosis has been established and a decision taken regarding initiation of immunomodulatory treatments, the majority of management decisions with which the physician will be confronted will concern symptom management. Whereas some symptoms are relatively easily treated, others are more difficult to manage. Management involves rehabilitation, pharmacological treatments and surgical procedures. Successful symptom management is a key determinant of quality of life for the patient and is the basis for improving physical and psychological function.

[1]  R. Newell,et al.  Treatment of fatigue in multiple sclerosis: a systematic review of the literature. , 2008, International journal of nursing practice.

[2]  T. Ziemssen,et al.  Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis , 2008, Health and quality of life outcomes.

[3]  K. Trinkaus,et al.  Comparative assessment of Yale Single Q uestion and Beck Depression Inventory Scale in screening for depression in multiple sclerosis , 2003, Multiple sclerosis.

[4]  Rohit Bakshi,et al.  Quality of life in patients with multiple sclerosis The impact of fatigue and depression , 2002, Journal of the Neurological Sciences.

[5]  P. Rieckmann,et al.  Symptomatic Treatment of Multiple Sclerosis , 2006, European Neurology.

[6]  D. Ehde,et al.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. , 2002, The American journal of psychiatry.

[7]  E. McDonald,et al.  Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management , 2010, Journal of Neurology.

[8]  D. Wade,et al.  Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis , 2010, Multiple sclerosis.

[9]  D. Mohr,et al.  Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. , 1997, Archives of neurology.

[10]  B. Saletu,et al.  Depression and quality of life in multiple sclerosis , 2001, Acta neurologica Scandinavica.

[11]  M. Weiner,et al.  Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis , 1994, Muscle & nerve.

[12]  H. Reichmann,et al.  Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis , 2009, Multiple sclerosis.

[13]  P. Rieckmann,et al.  Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. , 2008, Deutsches Arzteblatt international.

[14]  D. Mohr,et al.  Treatment of depression for patients with multiple sclerosis in neurology clinics , 2006, Multiple sclerosis.

[15]  Tjalf Ziemssen,et al.  Multiple sclerosis beyond EDSS: depression and fatigue , 2009, Journal of the Neurological Sciences.

[16]  T. Talvik,et al.  One question as a screening instrument for depression in people with multiple sclerosis , 2007, Clinical rehabilitation.

[17]  H. Rossman,et al.  A multimodal approach to managing the symptoms of multiple sclerosis , 2004, Neurology.

[18]  M. Amato,et al.  Quality of life in multiple sclerosis: the impact of depression, fatigue and disability , 2001, Multiple sclerosis.

[19]  C. Dickinson,et al.  Chronic fatigue syndrome—aetiological aspects , 1997, European journal of clinical investigation.

[20]  J. Oger,et al.  Depression and multiple sclerosis , 1996, Neurology.

[21]  L. Krupp,et al.  Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial , 2009, The Lancet.

[22]  J. Beaumont The MS symptom and impact diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  T. Ziemssen,et al.  Review: Brain—immune communication psychoneuroimmunology of multiple sclerosis , 2008, Multiple sclerosis.

[24]  W. Ammann,et al.  Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue , 1997, Neurology.

[25]  P. Peterson,et al.  Immunologically mediated fatigue: a murine model. , 1992, Clinical immunology and immunopathology.

[26]  A Achiron,et al.  Fatigue in multiple sclerosis compared with chronic fatigue syndrome , 1996, Neurology.

[27]  S. Gold,et al.  Endocrine and Cytokine Responses to Acute Psychological Stress in Multiple Sclerosis , 2002, Brain, Behavior, and Immunity.

[28]  U. Dalgas Rehabilitation and multiple sclerosis: hot topics in the preservation of physical functioning , 2011, Journal of the Neurological Sciences.

[29]  S. Patten,et al.  The effect of immunomodulatory treatment on multiple sclerosis fatigue , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[30]  S. Patten,et al.  Major depression in multiple sclerosis , 2003, Neurology.

[31]  B. Cohen Identification, causation, alleviation, and prevention of complications (ICAP) , 2008, Neurology.

[32]  P. Dorman,et al.  Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis , 1997, BMJ.

[33]  A F Long,et al.  The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  R. Zivadinov,et al.  Sexual dysfunction in multiple sderosis: a case-control study. 1. Frequency and comparison of groups , 1999, Multiple sclerosis.

[35]  R. Nixon,et al.  The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[36]  R. Zivadinov,et al.  Sexual dysfunction in multiple sclerosis: a 2-year follow-up study , 2001, Journal of the Neurological Sciences.

[37]  A Mauro,et al.  Depression is the main determinant of quality of life in multiple sclerosis: A classification-regression (CART) study , 2006, Disability and rehabilitation.